title: Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
abstract: OBJECTIVE
  To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy.
  
  
  METHODS
  Patients were randomly assigned to etanercept (25 mg twice weekly; sulfasalazine was discontinued at baseline), etanercept plus sulfasalazine (unchanged regimen of 2-3 g/day) or sulfasalazine in a double-blind, randomised, 2-year study in adult patients with active RA despite sulfasalazine therapy. Efficacy was assessed using the American College of Rheumatology criteria, disease activity scores (DAS) and patient-reported outcomes (PRO).
  
  
  RESULTS
  Demographic variables and baseline disease characteristics were comparable among treatment groups; mean DAS 5.1, 5.2 and 5.1 for etanercept (n = 103), etanercept plus sulfasalazine (n = 101) and sulfasalazine (n = 50), respectively. Withdrawal due to lack of efficacy was highest with sulfasalazine (26 (52%) vs 6 (6%) for either etanercept group, p<0.001). Patients receiving etanercept or etanercept plus sulfasalazine had a more rapid initial response, which was sustained at 2 years, than those receiving sulfasalazine: mean DAS 2.8, 2.5 versus 4.5, respectively (p<0.05); ACR 20 response was achieved by 67%, 77% versus 34% of patients, respectively (p<0.01) Overall, PRO followed a similar pattern; a clinically significant improvement in health assessment questionnaire was achieved by 76%, 78% versus 40% of patients, respectively (p<0.01). Commonly reported adverse events occurring in the etanercept groups were injection site reactions and pharyngitis/laryngitis (p<0.01).
  
  
  CONCLUSIONS
  Etanercept and etanercept plus sulfasalazine are efficacious for the long-term management of patients with RA. The addition of etanercept or substitution with etanercept should be considered as treatment options for patients not adequately responding to sulfasalazine.
authors.affiliation: Service d'Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France.
authors.forename: B
authors.initials: B
authors.lastname: Combe
authors.forename: C
authors.initials: C
authors.lastname: Codreanu
authors.forename: U
authors.initials: U
authors.lastname: Fiocco
authors.forename: M
authors.initials: M
authors.lastname: Gaubitz
authors.forename: P P
authors.initials: PP
authors.lastname: Geusens
authors.forename: T K
authors.initials: TK
authors.lastname: Kvien
authors.forename: K
authors.initials: K
authors.lastname: Pavelka
authors.forename: P N
authors.initials: PN
authors.lastname: Sambrook
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: R
authors.initials: R
authors.lastname: Khandker
authors.forename: A
authors.initials: A
authors.lastname: Singh
authors.forename: J
authors.initials: J
authors.lastname: Wajdula
authors.forename: S
authors.initials: S
authors.lastname: Fatenejad
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D000068800:Etanercept
references.citation: N Engl J Med. 1999 Jan 28;340(4):253-9
references.pmid: 9920948
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3372-7
references.pmid: 15728381
references.citation: Arthritis Rheum. 2006 Jan;54(1):68-75
references.pmid: 16385497
references.citation: Arthritis Rheum. 2003 Apr;48(4):1015-23
references.pmid: 12687543
references.citation: Ann Rheum Dis. 2007 Aug;66(8):1059-65
references.pmid: 17307765
references.citation: Clin Ther. 2003 Jun;25(6):1700-21
references.pmid: 12860493
references.citation: J Rheumatol. 2003 Dec;30(12):2563-71
references.pmid: 14719195
references.citation: Ann Rheum Dis. 2006 Oct;65(10):1357-62
references.pmid: 16606651
references.citation: Ann Rheum Dis. 2007 Oct;66(10):1356-62
references.pmid: 17293364
references.citation: J Rheumatol. 1993 Mar;20(3):557-60
references.pmid: 8478873
references.citation: Arthritis Rheum. 1995 Jun;38(6):727-35
references.pmid: 7779114
references.citation: Br J Rheumatol. 1997 May;36(5):551-9
references.pmid: 9189057
references.citation: Arthritis Rheum. 1999 Sep;42(9):1854-60
references.pmid: 10513799
references.citation: Ann Rheum Dis. 2007 Jun;66(6):732-9
references.pmid: 17329305
references.citation: Arthritis Rheum. 2004 Mar;50(3):953-60
references.pmid: 15022339
references.citation: Ann Rheum Dis. 2005 Mar;64(3):403-7
references.pmid: 15297281
references.citation: Arthritis Rheum. 1998 Sep;41(9):1552-63
references.pmid: 9751087
references.citation: Arthritis Rheum. 2004 May;50(5):1400-11
references.pmid: 15146409
references.citation: Ann Rheum Dis. 2000 Mar;59(3):223-6
references.pmid: 10700432
references.citation: Clin Exp Rheumatol. 1999 Nov-Dec;17(6 Suppl 18):S69-72
references.pmid: 10589361
references.citation: Br J Rheumatol. 1993 Aug;32(8):724-8
references.pmid: 8348276
references.citation: J Rheumatol. 2003 Jan;30(1):167-78
references.pmid: 12508408
references.citation: N Engl J Med. 2004 Jun 17;350(25):2591-602
references.pmid: 15201416
references.citation: Ann Rheum Dis. 2006 Nov;65(11):1478-83
references.pmid: 16464988
references.citation: Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii2-15
references.pmid: 17038465
references.citation: Lancet. 1999 Dec 4;354(9194):1932-9
references.pmid: 10622295
references.citation: Arthritis Rheum. 2003 Apr;48(4):944-54
references.pmid: 12687536